Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07008469 | Global Open-Label Extension Study of Del-desiran for the Treatment of DM1 | PHASE3 | ENROLLING BY_INVITATION | 230 | — | — | Jul 25, 2025 | Oct 1, 2030 | Apr 23, 2026 | 26 | United States, Canada +5 |
Incidence of treatment emergent adverse events
| Arm | Type | Description |
|---|---|---|
| Del-desiran | EXPERIMENTAL | Del-desiran (AOC 1001) will be administered seven times per year for up to 4 years. |
| Name | Type | Description |
|---|---|---|
| Del-desiran (AOC 1001) | DRUG | Del-desiran will be administered by intravenous (IV) infusion. |
FROM A PARENT STUDY Key Inclusion Criteria: * Completion of any prior AOC 1001 studies with satisfactory completion of dosing and follow-up assessments and satisfactory compliance with the protocol requirements of the parent study, as determined by the Investigator. Key Exclusion Criteria: * Bre...